Home >

Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

A letter from Gabriel N. Hortobagyi, MD, FACP, FASCO, Chair of ASCO's Global Oncology Leadership Task Force.
I have had a wonderful experience working with ASCO’s International Cancer Corps to start the Bhutan cancer registry.
We have discussed risk, biology, and the importance of complete reporting. So how do we decide to actually use RNI?
“Before I send in the prescription for this new treatment, let’s make sure you can afford it.” This is something I say in all of my consultations.
Whether you love or hate e-prescribing depends on whether you are writing, filling, or taking the pills.
This is the story of how a populist Congress approved the medication that wasn't, and oncologists in the country are waiting to see if an enfeebled president will be able to veto the bill.
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?
Deciding whether RNI works depends upon not only accurate risk assessment but also a better understanding of the disease. Here are some key elements of breast cancer and treatment that aren’t adequately decided just by looking at pathologic stage, grade, and surgery type.
Dr. Hudis will assume the role of ASCO and Conquer Cancer Foundation CEO on June 27, following the retirement of Dr. Allen Lichter.
Most times, a patient’s outpatient attending can be called upon to meet with the patient and their loved ones, especially if one is at a critical point in their own cancer journey. But, as is often the case in a busy academic practice, sometimes it’s just not possible.
In today’s medical environment of CTs, MRIs, and PETs, we rely heavily on technology in making our diagnoses. But what can we learn about our patients during a physical examination that we can’t learn from looking at a scan?
This year’s report clearly shows that strengthening the delivery system for cancer care has to be pursued just as aggressively as its research agenda.
To determine when radiation helps treat lymph nodes, we need to carefully interpret surgical findings and accurately stage breast cancer to best understand the risk of lymph node involvement.
Dr. Nagi El Saghir reflects on the challenges of delivering cancer care in regions rocked by hostilities, but sees hope in impactful educational and scientific meetings such as the recent Beirut Breast Cancer Conference (BBCC-4).
The Physician Mom Group on Facebook taught me an unexpected lesson about gratitude.
Two recently published large clinical trials, NCIC MA.20 and EORTC 22922, raised a lot of interest in and a lot of questions about when radiation helps for treating lymph nodes in breast cancer. The data are more complicated than often presented.
This is the story of how an eager chemistry professor and a well-intended but misguided federal judge transformed cancer care and drug development in Brazil into a convoluted soap opera.
When patients express fears and misgivings in clinic, there is an opportunity to dispel myths, diminish shame, and focus on living a full life despite cancer.

Pages